129 related articles for article (PubMed ID: 24340512)
1. The assessment of treatment efficacy in age related macular degeneration by evaluating the oxidative stress markers and OCT measurements.
Dănulescu R; Costin D
Rev Med Chir Soc Med Nat Iasi; 2013; 117(2):328-33. PubMed ID: 24340512
[TBL] [Abstract][Full Text] [Related]
2. Use of blood markers in early diagnosis of oxidative stress in age related macular degeneration.
Dănulescu R; Costin D
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1136-42. PubMed ID: 23700902
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
4. The impact of inflammation to the antioxidant defense parameters in AMD patients.
Čolak E; Majkić-Singh N; Žoric L; Radosavljević A; Kosanović-Jaković N
Aging Clin Exp Res; 2012 Dec; 24(6):588-94. PubMed ID: 22982945
[TBL] [Abstract][Full Text] [Related]
5. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration.
Lee SJ; Koh HJ
Ophthalmology; 2011 Jan; 118(1):101-10. PubMed ID: 20678805
[TBL] [Abstract][Full Text] [Related]
6. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
[TBL] [Abstract][Full Text] [Related]
7. Microperimetric changes after intravitreal bevacizumab injection for exudative age-related macular degeneration.
Ozdemir H; Karacorlu M; Senturk F; Karacorlu SA; Uysal O
Acta Ophthalmol; 2012 Feb; 90(1):71-5. PubMed ID: 20163371
[TBL] [Abstract][Full Text] [Related]
8. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion.
Singer MA; Bell DJ; Woods P; Pollard J; Boord T; Herro A; Porbandarwalla S
Retina; 2012 Jul; 32(7):1289-94. PubMed ID: 22466480
[TBL] [Abstract][Full Text] [Related]
9. Circulating antiretinal antibodies predict the outcome of anti-VEGF therapy in patients with exudative age-related macular degeneration.
Kubicka-Trząska A; Wilańska J; Romanowska-Dixon B; Sanak M
Acta Ophthalmol; 2012 Feb; 90(1):e21-4. PubMed ID: 21883989
[TBL] [Abstract][Full Text] [Related]
10. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
[TBL] [Abstract][Full Text] [Related]
11. Preferential hyperacuity perimeter as a functional tool for monitoring exudative age-related macular degeneration in patients treated by intravitreal ranibizumab.
Querques G; Querques L; Rafaeli O; Canoui-Poitrine F; Bandello F; Souied EH
Invest Ophthalmol Vis Sci; 2011 Sep; 52(9):7012-8. PubMed ID: 21885622
[TBL] [Abstract][Full Text] [Related]
12. Influence of age-related macular degeneration on macular thickness measurement made with fourier-domain optical coherence tomography.
Garas A; Papp A; Holló G
J Glaucoma; 2013 Mar; 22(3):195-200. PubMed ID: 22314250
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of changes in choroidal neovascularization secondary to age-related macular degeneration after anti-VEGF therapy using spectral domain optical coherence tomography.
You JY; Chung H; Kim HC
Curr Eye Res; 2012 May; 37(5):438-45. PubMed ID: 22510011
[TBL] [Abstract][Full Text] [Related]
14. Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration.
Jonas JB; Libondi T; Golubkina L; Spandau UH; Schlichtenbrede F; Rensch F
Acta Ophthalmol; 2010 Sep; 88(6):630-4. PubMed ID: 19432871
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML
Retina; 2007; 27(4):439-44. PubMed ID: 17420695
[TBL] [Abstract][Full Text] [Related]
16. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
17. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?
Schaal S; Kaplan HJ; Tezel TH
Ophthalmology; 2008 Dec; 115(12):2199-205. PubMed ID: 18930553
[TBL] [Abstract][Full Text] [Related]
18. Photoreceptor status after antivascular endothelial growth factor therapy in exudative age-related macular degeneration.
Sayanagi K; Sharma S; Kaiser PK
Br J Ophthalmol; 2009 May; 93(5):622-6. PubMed ID: 19208677
[TBL] [Abstract][Full Text] [Related]
19. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
